ArticleScientific reports2016
Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- Inhibition of Thioredoxin-Reductase by Auranofin as a Pro-Oxidant Anticancer Strategy for Glioblastoma: In Vitro and In Vivo Studies.International journal of molecular sciences · 2025Review
- Carmofur Exhibits Antimicrobial Activity AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Enhancing the therapeutical potential of metalloantibiotics using nano-based delivery systems.Beilstein journal of nanotechnology · 2025Review
- Auranofin-Loaded Chitosan Nanoparticles Demonstrate Potency against Triple-Negative Breast Cancer.ACS applied bio materials · 2024Article
- Antibacterial micro/nanomotors: current research progress, challenges, and opportunities.Theranostics · 2024Review
- Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.Antioxidants (Basel, Switzerland) · 2023Article
- Antitumoral and Antimicrobial Activities of Block Copolymer Micelles Containing Gold Bisdithiolate Complexes.Pharmaceutics · 2023Article
- Structural basis for the inhibitory mechanism of auranofin and gold(I) analogues againstComputational and structural biotechnology journal · 2023Article
- Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model.Pharmaceutics · 2022Article
- Auranofin and its analogs as prospective agents for the treatment of colorectal cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Zebrafish Models for the Safety and Therapeutic Testing of Nanoparticles with a Focus on Macrophages.Nanomaterials (Basel, Switzerland) · 2021Review
- Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.Redox biology · 2021Article
- Drug-Free Enzyme-Based Bactericidal Nanomotors against Pathogenic Bacteria.ACS applied materials & interfaces · 2021Article
- Recent Advances of Gold Compounds in Anticancer Immunity.Frontiers in chemistry · 2020Review
- The Use of Nanomedicine for Targeted Therapy against Bacterial Infections.Antibiotics (Basel, Switzerland) · 2019Review
- Composite thermoresponsive hydrogel with auranofin-loaded nanoparticles for topical treatment of vaginal trichomonad infection.Advanced therapeutics · 2019Article
- Nanomagnetite-embedded PLGA Spheres for Multipurpose Medical Applications.Materials (Basel, Switzerland) · 2019Article
- Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings.Frontiers in cellular and infection microbiology · 2019Article
- Mesoporous Silica Materials as Drug Delivery: "The Nightmare" of Bacterial Infection.Pharmaceutics · 2018Review
- Zirconyl Clindamycinphosphate Antibiotic Nanocarriers for Targeting Intracellular PersistingACS omega · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-loaded nanoparticles (NPs) can improve infection treatment by ensuring drug concentration at the right place within the therapeutic window. Poly(lactic-co-glycolic acid) (PLGA) NPs are able to enhance drug localization in target site and to sustainably release the entrapped molecule, reducing the secondary effects caused by systemic antibiotic administration. We have loaded auranofin, a gold compound traditionally used for treatment of rheumatoid arthritis, into PLGA NPs and their efficiency as antibacterial agent against two Gram-positive pathogens, Streptococcus pneumoniae and Streptococcus pyogenes was evaluated. Auranofin-PLGA NPs showed a strong bactericidal effect as cultures of multiresistant pneumococcal strains were practically sterilized after 6 h of treatment with such auranofin-NPs at 0.25 μM. Moreover, this potent bactericidal effect was also observed in S. pneumoniae and S. pyogenes biofilms, where the same concentration of auranofin-NPs was capable of decreasing the bacterial population about 4 logs more than free auranofin. These results were validated using a zebrafish embryo model demonstrating that treatment with auranofin loaded into NPs achieved a noticeable survival against pneumococcal infections. All these approaches displayed a clear superiority of loaded auranofin PLGA nanocarriers compared to free administration of the drug, which supports their potential application for the treatment of streptococcal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.